On March 16, 2024, the BIOCHINA2024/EBC successfully concluded at the Suzhou International Expo Center. With the theme ‘Collaboration Accelerates Innovation,’ the conference highlighted the development and prospects of the exosome field (including exosome drug delivery and MSC exosomes) within the broader context of innovative drug development.

On the afternoon of March 16, during the Nucleic Acid Drug Development Forum—a specialized track of the conference—Dr. Tinghe Wu, the Academic Founder and CEO of P.S.K Biosciences, presented a compelling keynote address entitled ‘Opportunities and Challenges in Brain-Targeted Delivery of Nucleic Acid Drugs Using Exosomes.’ Dr. Wu's talk focused on the major bottlenecks in the development of innovative nucleic acid drugs for CNS diseases, explored the advantages and challenges of using exosomes for nucleic acid drug delivery, and breakthroughs in the therapeutic application of engineering exosomes.

Dr. Wu emphasized that since the second half of 2022, his team has dedicated their efforts to overcoming the bottlenecks in process scale-up. Currently, P.S.K Bio's proprietary endogenous nucleic acid loading platform has completed concept validation and will soon be ready to share data publicly at the appropriate opportunity.

In closing, Dr. Wu took the opportunity to express his gratitude to Simcere Pharmaceutical for their unwavering support, trust, and invaluable assistance in advancing the exosome drug delivery technology platform team. He also extended sincere thanks to the first-round investors of P.S.K Bio and to the BioChina2024 (EBC) organizing committee, as well as Dr. Xu for the invitation. He expressed his expectation for future collaboration opportunities with domestic and international companies in the development of targeted drug delivery for innovative nucleic acid drugs.

Finally, he also hopes that P.S.K Bio's advantages in endogenous loading of exosome-based nucleic acid drugs and the establishment of mature CMC processes can assist companies dedicated to developing siRNA and mRNA drugs for CNS diseases.